Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. | Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. Months after sharing obesity data that ...

The trial followed 3,533 people in 28 countries with type 2 diabetes and moderate to severe kidney disease. The results demonstrate delayed progression of CKD in the semaglutide group with a 24% ...

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

slows chronic kidney disease (CKD) progression and reduces all-cause mortality risk compared with dipeptidyl peptidase-4 inhibitors (DPP-4i) in male patients with moderate to severe CKD and type 2 ...

U.S. medical services providers are seeing the greatest numbers of flu cases since the 2009-2010 flu season, the Centers for ...

Children with AAV and kidney disease face increased risks for long-term renal damage at 1 year, despite the majority achieving inactive renal disease by this time.

More than 35 million people in the U.S. have chronic kidney disease (CKD), a condition in which the kidneys are damaged and ...

Atherosclerosis cardiovascular disease (ASCVD)-related mortality is higher in patients with lupus nephritis (LN) compared ...